ArticleImmunology2013
The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease.
Article in Immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Glycoprotein non-metastatic melanoma protein B is a potential biomarker for arthroplasty aseptic loosening.Scientific reports · 2025Article
- GPNMB: a potent inducer of immunosuppression in cancer.Oncogene · 2022Review
- Expression pattern and clinical value of Key RNA methylation modification regulators in ischemic stroke.Frontiers in genetics · 2022Article
- Glycoprotein nonmetastatic melanoma protein B: A key mediator and an emerging therapeutic target in autoimmune diseases.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Review
- Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.Future science OA · 2016Article
- Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell-Suppressor Mechanisms.The Journal of investigative dermatology · 2016Article
- Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives.Frontiers in immunology · 2016Review
- Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis.Scientific reports · 2015Article
- The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.Cell communication and signaling : CCS · 2015Article
- DC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma.The Journal of investigative dermatology · 2014Article
- The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Syndecan-4 signaling at a glance.Journal of cell science · 2013Review
- Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.OncoTargets and therapy · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Acute graft-versus-host disease (GVHD) is the most important cause of mortality after allogeneic haematopoietic stem cell transplantation. Allo-reactive T cells are the major mediators of GVHD and the process is regulated by positive and negative regulators on antigen-presenting cells (APC). Because the significance of negative regulators in GVHD pathogenesis is not fully understood, and having discovered that syndecan-4 (SD-4) on effector T cells mediates the inhibitory function of DC-HIL on APC, we proposed that SD-4 negatively regulates the T-cell response to allo-stimulation in acute GVHD, using SD-4 knockout mice. Although not different from their wild-type counterparts in responsiveness to anti-CD3 stimulation, SD-4(-/-) T cells lost the capacity to mediate the inhibitory function of DC-HIL and were hyper-reactive to allogeneic APC. Moreover, infusion of SD-4(-/-) T cells into sub-lethally γ-irradiated allogeneic mice worsened mortality, with hyper-proliferation of infused T cells in recipients. Although there my be little or no involvement of regulatory T cells in this model because SD-4 deletion had no deleterious effect on T-cell-suppressive activity compared with SD-4(+/+) regulatory T cells. We conclude that SD-4, as the T-cell ligand of DC-HIL, is a potent inhibitor of allo-reactive T cells responsible for GVHD and a potentially useful target for treating this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.